Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk

4区医学 Q1 Medicine

Atherosclerosis. Supplements Pub Date : 2020-12-01 DOI:10.1016/j.atherosclerosissup.2021.01.001

Lale Tokgözoğlu , Manuela Casula , Angela Pirillo , Alberico L. Catapano

{"title":"Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk","authors":"Lale Tokgözoğlu , Manuela Casula , Angela Pirillo , Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.001","DOIUrl":null,"url":null,"abstract":"<div><p>The 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several differences in the recommendations, including the definition of very-high-risk patient category, the recommendations for some categories of patients, such as those with diabetes, familial hypercholesterolemia, chronic kidney disease, and aged patients, and the use of ezetimibe and PCSK9 inhibitors. These differences suggest that multiple approaches can be used to manage lipid abnormalities in the context of cardiovascular risk reduction.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e1-e5"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.001","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis. Supplements","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567568821000015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

Abstract

The 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several differences in the recommendations, including the definition of very-high-risk patient category, the recommendations for some categories of patients, such as those with diabetes, familial hypercholesterolemia, chronic kidney disease, and aged patients, and the use of ezetimibe and PCSK9 inhibitors. These differences suggest that multiple approaches can be used to manage lipid abnormalities in the context of cardiovascular risk reduction.

Abstract Image

查看原文本刊更多论文

欧美血脂管理指南降低心血管风险的异同

美国和欧洲最近发布的2018年美国心脏协会/美国心脏病学会/多学会(AHA/ACC/MS)血液胆固醇管理指南和2019年欧洲心脏病学会/欧洲动脉粥样硬化学会(ESC/EAS)血脂异常管理指南:脂质改变以降低心血管风险，为管理血脂水平提供了基于最新证据的新建议。尽管有许多共同点，但建议中也存在一些差异，包括对高危患者类别的定义，对某些类别患者(如糖尿病、家族性高胆固醇血症、慢性肾病和老年患者)的建议，以及依zetimibe和PCSK9抑制剂的使用。这些差异表明，在降低心血管风险的背景下，可以使用多种方法来管理脂质异常。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Atherosclerosis. Supplements 医学-外周血管病

CiteScore

4.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations.